Wellcome Open Res. 2016 Nov 15;1:10.
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.
Lewin A, Hamilton S, Witkover A, Langford P, Nicholas R, Chataway J, Bangham CR.
Background A major cause of disability in secondary progressive multiple sclerosis (SPMS) is progressive brain atrophy, whose pathogenesis is not fully understood. The objective of this study was to identify protein biomarkers of brain atrophy in SPMS. Methods We used surface-enhanced laser desorption-ionization time-of-flight mass spectrometry to carry out an unbiased search for serum proteins whose concentration correlated with the rate of brain atrophy, measured by serial MRI scans over a 2-year period in a well-characterized cohort of 140 patients with SPMS. Protein species were identified by liquid chromatography-electrospray ionization tandem mass spectrometry. Results There was a significant (p<0.004) correlation between the rate of brain atrophy and a rise in the concentration of proteins at 15.1 kDa and 15.9 kDa in the serum. Tandem mass spectrometry identified these proteins as alpha-haemoglobin and beta-haemoglobin, respectively. The abnormal concentration of free serum haemoglobin was confirmed by ELISA (p<0.001). The serum lactate dehydrogenase activity was also highly significantly raised (p<10-12) in patients with secondary progressive multiple sclerosis. Conclusions An underlying low-grade chronic intravascular haemolysis is a potential source of the iron whose deposition along blood vessels in multiple sclerosis plaques contributes to the neurodegeneration and consequent brain atrophy seen in progressive disease. Chelators of free serum iron will be ineffective in preventing this neurodegeneration, because the iron (Fe2+) is chelated by haemoglobin.
This work is performed using the serum samples from the MS-STAT study which showed a small yet significant reduction in the rate of brain volume with high-dose (80mg) simvastatin. The aim of this study was to find potential biomarkers of brain atrophy.
Here, Lewin et al. report a new potential candidate; free serum haemoglobin. It does not come as news to me that this wasn't picked up by other seasoned proteomics researchers before, as it's easy to overlook proteins where there is lack of substantiating evidence in the disease under question. That is, this may be present in previous screens but not flagged as significant by the researchers reporting it! In the same way I'm surprised that neurofilament proteins were not flagged in Lewin's work as I know them to be a consistent finding in sample screens for progressive MS and increased with brain volume loss...
Proteomics also suffers from pre-analytical variations i.e. sample processing, storage etc., which may lead to differential findings from group to group. This is why, a confirmatory check is needed (i.e. the same change is demonstrated by another methodology, for example ELISA), which is what is performed here. They demonstrate that there is a similar rise in serum haemoglobin using commercial test (provided by Abcam). But they do not provide any validation data on this, which is a paramount requirement in this field of research. The European Biomarker Consortium provided a guidance document with regard to reporting on new biomarkers (Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Álvarez-Cermeño JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G), to avoid scientists spending time on researching random findings! I suppose it's fine because the authors state that "these results do not suggest that free serum haemoglobin concentration
is useful in the differential diagnosis of neurological disease", which is smart!
Let's look at the hypothesis, this is an interesting one and well worth taking a second look. We know that in all neurodegenerative disorders, including MS, there is an increase in the iron deposition in the brain. Normally, there is iron bound to haemoglobin in red blood cells. When you spin blood to obtain the serum the red blood cells (which are heavier) separate out at the bottom of the tube. Therefore, any free blood in the sample, outside of rubbish venepuncture technique (I'm assuming that haemolysed samples were excluded prior to analysis, as this is a requirement for proteomic studies), is indicative of blood break down (or haemolysis). There is then a possibility, that this may cause problems (see above figure for a potential mechanism); although I don't think this is a direct causal evidence for brain atrophy (i.e. may be epiphenomena), as autoimmune haemolytic anaemia (blood disorder which is both genetic and caused by other illnesses) has no reported mention of brain volume loss. Clearly, more work is needed in this area. Moreover, other groups looking at this also need to examine haptoglobin levels, as haptoglobin binds free serum haemoglobin and genetic variations in haptoglobin between individuals has been reported to affect free serum haemoglobin levels.
Finally, there is no observed treatment effect on free serum haemoglobin of high-dose simvastatin. Lewin et al. state "This effect was independent of the beneficial treatment effect of
simvastatin, because there was no association between free haemoglobin
concentration and simvastatin treatment", they also state "The results presented here show that a rise in the concentration of free
haemoglobin in the serum was associated with the rate of brain atrophy
in this cohort of patients with SPMS". Are they, therefore, implying that high-dose simvastatin does not in fact lower the likelihood of brain atrophy! Maybe, I'm putting words in their mouth!! Please place me on a direct line to a good statistician!
Labels: free serum haemoglobin, haemolysis, MS-STAT, secondary progressive MS